Table 3.
Median progression-free survival and univariable analysis of prognostic factors for progression-free survival for all patients and divided by biological subtype
| Number of events/patients | Median PFS, months (95% CI) |
Log rank p-value | Hazard Ratio (95% CI) | Wald p-value | |
|---|---|---|---|---|---|
| All patients | 364/439 | 4.1 (3.7–4.4) | < 0.001 | ||
| ER + /HER2- | 229/279 | 4.6 (4.2–5.2) | Ref. | ||
| HER2 | 57/68 | 3.9 (2.9–5.5) | 1.03 (0.77–1.38) | 0.84 | |
| TNBC | 78/92 | 2.4 (2.1–3.0) | 1.98 (1.53–2.57) | < 0.001 | |
| All patients | |||||
| DRFi, years | |||||
| 1st tertile (≤ 2.8) | 99/122 | 2.8 (2.3–4.4) | 0.30 | Ref. | |
| 2nd tertile (> 2.8–7.0) | 102/121 | 4.4 (3.7–5.0) | 0.90 (0.68–1.19) | 0.47 | |
| 3rd tertile (> 7.0) | 102/121 | 3.9 (3.8–5.3) | 0.79 (0.60–1.05) | 0.10 | |
| De novo metastatic | 61/75 | 3.9 (3.4–4.6) | 1.03 (0.74–1.42) | 0.87 | |
| Linear | 0.99 (0.97–1.01) | 0.21 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 227/274 | 4.3 (3.7–4.6) | 0.65 | Ref. | |
| > 2 | 137/165 | 3.9 (3.6–4.6) | 1.05 (0.85–1.07) | 0.66 | |
| Linear | 0.94 (0.86–1.03) | 0.19 | |||
| ADPT, months | |||||
| 1st tertile (≤ 6.3) | 126/146 | 2.8 (2.3–3.9) | 0.001 | Ref. | |
| 2nd tertile (> 6.3–10.1) | 124/145 | 4.4 (3.8–5.0) | 0.72 (0.56–0.92) | 0.009 | |
| 3rd tertile (> 10.1) | 111/145 | 4.7 (4.0–5.3) | 0.62 (0.42–0.69) | < 0.001 | |
| Linear | 0.96 (0.94–0.98) | < 0.001 | |||
| ER + /HER2- | |||||
| DRFi, years | |||||
| 1st tertile (≤ 4.3) | 63/78 | 4.4 (3.7–7.1) | 0.44 | Ref. | |
| 2nd tertile (> 4.3–8.8) | 65/77 | 5.0 (4.4–6.1) | 1.06 (0.75–1.51) | 0.73 | |
| 3rd tertile (> 8.8) | 67/77 | 4.6 (3.6–5.3) | 1.29 (0.91–1.82) | 0.16 | |
| De novo metastatic | 34/47 | 4.4 (3.7–7.3) | 1.27 (0.83–1.94) | 0.27 | |
| Linear | 1.01 (0.99–1.03) | 0.45 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 143/175 | 4.6 (3.7–5.3) | 0.91 | Ref. | |
| > 2 | 86/104 | 4.6 (4.3–5.3) | 0.99 (0.75–1.29) | 0.91 | |
| Linear | 0.91 (0.80–1.02) | 0.11 | |||
| ADPT, months | |||||
| 1st tertile (≤ 6.5) | 79/93 | 4.1 (3.0–5.2) | 0.36 | Ref. | |
| 2nd tertile (> 6.5–10.4) | 80/92 | 5.3 (4.4–7.2) | 0.80 (0.58–1.09) | 0.15 | |
| 3rd tertile (> 10.4) | 68/92 | 4.6 (3.7–5.3) | 0.88 (0.64–1.22) | 0.45 | |
| Linear | 0.98 (0.95–1.00) | 0.039 | |||
| HER2 + | |||||
| DRFi, years | |||||
| 1st tertile (≤ 2.4) | 14/18 | 5.0 (2.5–*) | 0.62 | Ref. | |
| 2nd tertile (> 2.4–4.9) | 14/17 | 3.7 (2.1–7.5) | 1.65 (0.75–3.6) | 0.21 | |
| 3rd tertile (> 4.9) | 14/18 | 3.1 (1.8–*) | 1.24 (0.58–2.66) | 0.58 | |
| De novo metastatic | 15/15 | 3.9 (3.4–9.1) | 1.46 (0.68–3.13) | 0.33 | |
| Linear | 0.97 (0.92–1.03) | 0.35 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 27/32 | 5.0 (2.3–7.5) | 0.21 | Ref. | |
| > 2 | 30/36 | 3.6 (2.5–5.5) | 1.40 (0.82–2.38) | 0.22 | |
| Linear | 1.06 (0.87–1.28) | 0.57 | |||
| ADPT, months | |||||
| 1st tertile (≤ 7.8) | 18/23 | 2.9 (1.8–6.7) | 0.19 | Ref. | |
| 2nd tertile (> 7.8–12.4) | 20/22 | 2.3 (2.1–6.9) | 0.71 (0.37–1.36) | 0.30 | |
| 3rd tertile (> 12.4) | 19/23 | 5.0 (4.1–9.1) | 0.55 (0.29–1.05) | 0.071 | |
| Linear | 0.95 (0.90–1.00) | 0.063 | |||
| TNBC | |||||
| DRFi, years | |||||
| 1st tertile (≤ 1.4) | 23/27 | 2.3 (1.8–2.6) | 0.004 | Ref. | |
| 2nd tertile (> 1.4–2.8) | 21/26 | 2.3 (1.7–4.5) | 0.49 (0.26–0.92) | 0.026 | |
| 3rd tertile (> 2.8) | 22/26 | 3.8 (3.0–6.0) | 0.32 (0.17–0.60) | < 0.001 | |
| De novo metastatic | 12/13 | 2.2 (1.9–*) | 0.68 (0.34–1.39) | 0.29 | |
| Linear | 0.93 (0.85–1.01) | 0.075 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 57/67 | 2.4 (2.1–3.0) | 0.48 | Ref. | |
| > 2 | 21/25 | 2.6 (1.9–3.9) | 1.20 (0.72–1.99) | 0.49 | |
| Linear | 0.99 (0.76–1.28) | 0.92 | |||
| ADPT, months | |||||
| 1st tertile (≤ 5.0) | 28/31 | 1.9 (1.5–2.7) | 0.001 | Ref. | |
| 2nd tertile (> 5.0–8.7) | 24/31 | 2.2 (1.9–4.4) | 0.60 (0.35–1.05) | 0.074 | |
| 3rd tertile (> 8.7) | 25/30 | 3.8 (2.6–5.0) | 0.34 (0.19–0.62) | < 0.001 | |
| Linear | 0.92 (0.86–0.97) | 0.002 |
ADPT average duration of previous treatment lines, DRFi distant recurrence-free interval, PFS progression-free survival